Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Hematology (2019)
  • Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2019) CA
  • Fellowship: Stanford University Hematology and Oncology Fellowship (2019) CA
  • Board Certification: American Board of Pediatrics, Pediatrics (2014)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2014)
  • Residency: LACplusUSC Internal Medicine and Pediatric Residency (2014) CA
  • Medical Education: University of Southern California Keck School of Medicine Registrar (2010) CA

Contact

  • Academic
    University - Academic staff Department: Pediatrics - Hematology/Oncology Position: Clinical Assistant Professor
    University - Staff Department: Medicine - Med/Hematology Position: Clinical Assistant Professor
  • Clinical Pediatric Hematology and Oncology 1000 Welch Rd Ste 300 MC 5798 Palo Alto, CA 94304 (650) 498-6937 (fax)

Additional Info

  • Mail Code: 5156

All Publications

  • A Blueprint for Identifying Phenotypes and Drug Targets in Complex Disorders with Empirical Dynamics. Patterns (New York, N.Y.) Krieger, M. S., Moreau, J. M., Zhang, H., Chien, M., Zehnder, J. L., Craig, M. 2020; 1 (9): 100138

    Abstract

    A central challenge in medicine is translating from observational understanding to mechanistic understanding, where some observations are recognized as causes for the others. This can lead not only to new treatments and understanding, but also to recognition of novel phenotypes. Here, we apply a collection of mathematical techniques (empirical dynamics), which infer mechanistic networks in a model-free manner from longitudinal data, to hematopoiesis. Our study consists of three subjects with markers for cyclic thrombocytopenia, in which multiple cells and proteins undergo abnormal oscillations. One subject has atypical markers and may represent a rare phenotype. Our analyses support this contention, and also lend new evidence to a theory for the cause of this disorder. Simulations of an intervention yield encouraging results, even when applied to patient data outside our three subjects. These successes suggest that this blueprint has broader applicability in understanding and treating complex disorders.

    View details for DOI 10.1016/j.patter.2020.100138

    View details for PubMedID 33336196

  • Impact of in utero transfusions in fetuses with hydrops fetalis due to alpha thalassemia Lianoglou, B. R., Gonzalez, V., Velez, J., Norton, M. E., Chen, B., Finley, B., Hirata, G., Ogasawara, K., MacKenzie, T. C., Brown, R. N., Sanchez-Embrey, E., Shaw, S. W., Foe, M., Bitanga, M., Chien, M., Stumbaugh, T., Thompson, A. A., Viprakasit, V., Volanakis, E. J., Vichinsky, E. MOSBY-ELSEVIER. 2020: S300–S301

    View details for DOI 10.1016/j.ajog.2019.11.474

    View details for Web of Science ID 000504997300457

  • CLINICAL OUTCOME OF HB KHARTOUM/beta THALASSEMIA COMPOUND HETEROZYGOSITY: A GLIMPSE INTO HOMOZYGOUS HB KHARTOUM Chien, M., Glader, B. WILEY. 2018

    View details for Web of Science ID 000428851200076

  • ANTICOAGULATION FOR TREATMENT OF PAIN IN VENOUS MALFORMATIONS Chien, M., Kreimer, S., Teng, J., Marqueling, A., Jeng, M. WILEY. 2018

    View details for Web of Science ID 000428851200243